

Claim 7, delete "claims 19" and insert therefor --
claims 21 --.

Claim 10, delete "claims 19" and insert therefor --
claims 21 --.

Claim 11, delete "claim 19" and insert therefor --
claim 21 --.

Delete claims 19-20.

Add claims 21-22.

21. *Cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of such ester thereof, or a compound which, upon administration to a recipient, is capable of providing *cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or an antivirally active metabolite or residue thereof substantially free of the corresponding (+)-enantiomer.

22. *Cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt, ester, or salt of such ester thereof, or any other compound which, upon administration to a recipient, is capable of providing *cis*-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or an antivirally active metabolite or residue thereof.

REMARKS

Applicants have cancelled claims 19-20 and added new claims 21-22 to identify more clearly the claimed subject matter. New claims 21-22 are identical to cancelled claims 19-20 except that the term "pharmaceutically acceptable derivative" has been replaced with its precise definition. Support for new